Bioscience Managers' first fund achieves 24.7% IRR
Bioscience Managers revealed that its Australian Bioscience Fund I healthcare fund has returned capital to investors at an annual internal rate of return of 24.7%.
Since its inception in July 2008, the fund called $35 million and ended with $56 million returned, a closing unit price of $1.76 per dollar invested, the fund manager said.
Australian Bioscience I was the first fund run by Bioscience Managers since it was established from the former IB Managers.
It focused on investments in mid-stage healthcare and life science investments, including Alchemia (ASX:ACL), Bionomics (ASX:BNO), Acrux (ASX:ACR) and HeartWare International (ASX:HIN).
The fund’s minimum commitment was $4 million, and investors included Telstra Super, Asia Union Investments, Meat Industry Employees Superannuation Fund and the ANU.
Bioscience Managers Managing Director Jeremy Curnock Cook said the fund has outperformed the S&P/ASX200 Accumulation Index by 68%, “despite the volatility in the past six years and investing in what is regarded as a high-risk sector”.
The company’s second fund, Asia Pacific Healthcare Fund II, will have its final close in September. The fund seeks to raise up to $100 million and has invested in companies including Nexvet Biopharma, Avita Medical (ASX:AVH), AmpliPhi Biosciences and Rex Bionics
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
